ScreenerHero

ZURA Zura Bio Limited

NAS · US · Healthcare · Biotechnology · zurabio.com
4.170USD+5.30%Mkt Cap: 399.61M $P/E: —

Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for autoimmune and inflammatory disorders in the United States. The company develops Tibulizumab, a humanized IgG4 single-chain variable fragme…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap399.61M USD
Enterprise Value174.35M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-68.65M USD
Revenue/Share—
Last Price4.170 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees40
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.44
PEG—
EV/EBITDA-1.88
EV/Revenue—
P/S—
P/B1.92
EPS (TTM)-1.13
EPS (Forward)-0.61
52W Range
2.76030% of range7.440
52W High7.440 USD
52W Low2.760 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-67.61%
ROA-60.25%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-64.81M USD
CapEx (TTM)113.00K USD
FCF Margin—
FCF Yield-12.22%
Net Debt-205.13M USD
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity—
Current Ratio12.90
Quick Ratio12.57
Book Value/Sh2.06 USD
Cash/Share2.14 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)18.00 USD
Upside (mean)+331.7%
Target Range11.00 USD – 26.00 USD
11.00+331.7% to mean26.00
# Analysts6
Ownership
Shares Out.95.83M
Float50.71M
Insiders18.92%
Institutions87.86%
Short Interest
Short Ratio5.4d
Short % Float13.02%
Short % Out.9.75%
Shares Short9.34M
Short (prev mo.)11.44M
Technical
SMA 505.282 (-21.1%)
SMA 2005.322 (-21.6%)
Beta0.01
S&P 52W Chg15.78%
Avg Vol (30d)1.94M
Avg Vol (10d)2.45M
Technical Indicators
RSI (14)37.1
MACD-0.4013
MACD Signal-0.3740
MACD Hist.-0.0272
BB Upper6.135 USD
BB Middle4.644 USD
BB Lower3.152 USD
BB Width64.22%
ATR (14)0.3524 USD
Vol Ratio (20d)1.07x